These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 15983549

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation.
    Hamilton BK, Rybicki L, Dean R, Majhail NS, Haddad H, Abounader D, Hanna R, Sobecks R, Duong H, Hill BT, Copelan E, Bolwell B, Kalaycio M.
    Am J Hematol; 2015 Feb; 90(2):144-8. PubMed ID: 25353395
    [Abstract] [Full Text] [Related]

  • 4. MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings.
    Piñana JL, Valcárcel D, Fernández-Avilés F, Martino R, Rovira M, Barba P, Martínez C, Brunet S, Sureda A, Carreras E, Sierra J.
    Bone Marrow Transplant; 2010 Sep; 45(9):1449-56. PubMed ID: 20140024
    [Abstract] [Full Text] [Related]

  • 5. [Combination of mycophenolate mofetil with cyclosporine A and methotrexate for the prophylaxes of acute graft versus host disease in allogeneic peripheral stem cell transplantation].
    Wang J, Song X, Zhang W, Tong S, Hou J, Chen L, Lou J, Li H, Ding X, Min B.
    Zhonghua Yi Xue Za Zhi; 2002 Apr 25; 82(8):507-10. PubMed ID: 12133492
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings.
    Neumann F, Graef T, Tapprich C, Vaupel M, Steidl U, Germing U, Fenk R, Hinke A, Haas R, Kobbe G.
    Bone Marrow Transplant; 2005 Jun 25; 35(11):1089-93. PubMed ID: 15821769
    [Abstract] [Full Text] [Related]

  • 8. Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies.
    Ostronoff F, Ostronoff M, Souto-Maior AP, Domingues M, Sucupira A, Manso DA, de Lima AK, Monteiro PG, Florêncio R, Calixto R.
    Clin Transplant; 2009 Jun 25; 23(1):33-8. PubMed ID: 18727660
    [Abstract] [Full Text] [Related]

  • 9. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation.
    Bornhäuser M, Schuler U, Pörksen G, Naumann R, Geissler G, Thiede C, Schwerdtfeger R, Ehninger G, Thiede HM.
    Transplantation; 1999 Feb 27; 67(4):499-504. PubMed ID: 10071016
    [Abstract] [Full Text] [Related]

  • 10. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP, Chen CS, Tai BC, Hwang WY, Tan LK, Ng HY, Linn YC, Koh MB, Goh YT, Tan B, Lim S, Lee YM, Tan KW, Liu TC, Ng HJ, Loh YS, Mow BM, Tan DC, Tan PH.
    Biol Blood Marrow Transplant; 2007 Jul 27; 13(7):790-805. PubMed ID: 17580257
    [Abstract] [Full Text] [Related]

  • 11. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
    Bhatia M, Militano O, Jin Z, Figurski M, Shaw L, Moore V, Morris E, Tallamy B, van deVen C, Ayello J, Baxter-Lowe L, Satwani P, George D, Bradley MB, Garvin J, Cairo MS.
    Biol Blood Marrow Transplant; 2010 Mar 27; 16(3):333-43. PubMed ID: 19835971
    [Abstract] [Full Text] [Related]

  • 12. A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients.
    Windreich RM, Goyal RK, Joshi R, Kenkre TS, Howrie D, Venkataramanan R.
    Biol Blood Marrow Transplant; 2016 Apr 27; 22(4):682-689. PubMed ID: 26740371
    [Abstract] [Full Text] [Related]

  • 13. Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
    Pérez-Simón JA, Martino R, Caballero D, Valcarcel D, Rebollo N, de la Cámara R, de Oteiza JP, Heras I, Calvo MV, Sierra J, San Miguel JF, Grupo Español de Trasplante Hematopoyético (GETH).
    Biol Blood Marrow Transplant; 2008 Jun 27; 14(6):664-71. PubMed ID: 18489992
    [Abstract] [Full Text] [Related]

  • 14. Combination of low-dose mycophenolate mofetil with cyclosporine and methotrexate as GVHD prophylaxis in unrelated donor allogeneic stem cell transplantation.
    Zhu X, Lai X, Luo Y, Shi J, Tan Y, Zheng W, He J, Xie W, Li L, Zhang J, Ye X, Lin M, Cai Z, Huang H.
    Leuk Res; 2013 Sep 27; 37(9):1046-51. PubMed ID: 23849987
    [Abstract] [Full Text] [Related]

  • 15. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
    Sabry W, Le Blanc R, Labbé AC, Sauvageau G, Couban S, Kiss T, Busque L, Cohen S, Lachance S, Roy DC, Roy J.
    Biol Blood Marrow Transplant; 2009 Aug 27; 15(8):919-29. PubMed ID: 19589481
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
    Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, Kim D, Ringden O, Urbano-Ispizua A, Saad A, Savani BN, Cooper B, Marks DI, Socie G, Schouten HC, Schoemans H, Abdel-Azim H, Yared J, Cahn JY, Wagner J, Antin JH, Verdonck LF, Lehmann L, Aljurf MD, MacMillan ML, Litzow MR, Solh MM, Qayed M, Hematti P, Kamble RT, Vij R, Hayashi RJ, Gale RP, Martino R, Seo S, Hashmi SK, Nishihori T, Teshima T, Gergis U, Inamoto Y, Spellman SR, Arora M, Hamilton BK.
    Biol Blood Marrow Transplant; 2019 Jan 27; 25(1):73-85. PubMed ID: 30153491
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation.
    Hamad N, Shanavas M, Michelis FV, Uhm J, Gupta V, Seftel M, Kuruvilla J, Lipton JH, Messner HA, Kim DD.
    Am J Hematol; 2015 May 27; 90(5):392-9. PubMed ID: 25615933
    [Abstract] [Full Text] [Related]

  • 20. Comparison of cyclosporine and tacrolimus combined with mycophenolate mofetil in prophylaxis for graft-versus-host disease after reduced-intensity umbilical cord blood transplantation.
    Miyamoto T, Takashima S, Kato K, Takase K, Yoshimoto G, Yoshida S, Henzan H, Osaki K, Kamimura T, Iwasaki H, Eto T, Teshima T, Nagafuji K, Akashi K.
    Int J Hematol; 2017 Jan 27; 105(1):92-99. PubMed ID: 27686673
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.